Philip Morris International Progresses Towards Smoke-Free Future

Sep.16.2022
Philip Morris International Progresses Towards Smoke-Free Future
PMI aims to end cigarette sales and promote smoke-free alternatives, with decreasing sales and increasing investment in innovation products.

PMI is often asked if it truly intends to end cigarette sales.


The answer is: yes.


Philip Morris International acknowledges that the decline in cigarette sales - or broadly speaking, the decline in the combustible product portfolio of PMI - is a necessary component in achieving its ambitions for a smoke-free future.


Fimo International is rapidly making progress towards this goal.


According to data publicly released by Fumo International, their cigarette sales have been on a downward trend for the past decade.


The annual sales volume of cigarettes has declined from 91.5 billion units in 2011 to 62.5 billion units in 2021, decreasing every year over the past nine years.


Furthermore, PMI has set a target for the total shipment of combustible products to be below 550 billion units by 2025, as stated in their 2021 comprehensive report.


The cigarette shipments of PMI (Phillip Morris International) have decreased from 915 billion in 2011 to 625 billion in 2021.


Phimo International aims to ultimately replace cigarettes with smoke-free alternatives.


Since 2008, Philip Morris International has invested over 9 billion dollars in the research and development, product development, production capabilities, scientific validation, and understanding of adult smokers for these innovative products.


This is a successful investment as an increasing number of adult smokers are switching to FiMO International's heated tobacco products, leading to a reduction in cigarette transportation volume.


As of June 30th, 2022, approximately 13.2 million adult smokers have switched to smoke-free alternatives and quit smoking.


The shipment volume of PhiMo International's heated tobacco devices has increased from 7 billion in 2016 to 95 billion in 2021.


These figures are transparently released annually by Fimo International for anyone to access.


Although the optimal choice for any smoker is to completely quit smoking and nicotine, scientifically proven smokeless products are a better option for adult smokers who would otherwise continue smoking.


According to Moira Gilchrist, VP of Strategic and Scientific Communication at Philip Morris International, the company's decision to unilaterally stop selling cigarettes tomorrow will not change anything. "Because it doesn't eliminate the demand for cigarettes. The demand will remain, and others will simply fill it, whether it be competitors or participants in the black market.


Our transition is more significant because we are striving to reduce the long-term demand for cigarettes, ensuring that the decline in the number of smokers continues - and may even accelerate further.


These numbers cannot be ignored," said Stefano Volpetti, President of the PMI Smoke-Free Products category and Chief Consumer Officer. "They clearly depict the transformation that Philip Morris International is driving - first, providing a range of better alternatives for adult smokers and secondly, accelerating smoking cessation.


Our scientific evidence confirms that PMI's smoke-free products, while not without risk, are a better choice than cigarettes for adults who would otherwise continue to smoke.


With support from the industry, stakeholders, and civil society, we believe that cigarette sales can come to an end in many countries within 10 to 15 years. This would be an enduring achievement for the global population of 1 billion smokers, global public health, and our company.


As of June 30, 2022, Philip Morris International (PMI) estimates that approximately 13.2 million adult individuals worldwide (excluding Russia and Ukraine) have switched to their heated tobacco products and quit smoking. These user statistics are reflective of PMI's estimates, which are based on consumer statements and sample-based statistical evaluations, with an average margin of error of +/-5% within the 95% confidence interval in key quantity markets. The accuracy and reliability of user statistics may vary depending on the maturity of individual markets and the availability of information.


Statement:


The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is for industry exchange and research purposes only.


Due to the limitations of the translator's skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS’ viewpoints and statements on any domestic, Hong Kong, Macau, Taiwan, or international issues are entirely aligned with those of the Chinese government.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07